Also, considering that humanized OX40 agonists have already been developed and successfully passed the phase I clinical trials (13), this immunotherapeutic mAb approach may serve as an effective adjuvant to include along with cancer vaccines. This evidence concerns the gene TNFRSF4 and cancer.